Dec. 12 at 1:54 PM
$CRDL For perspective, here are several early-stage biotechs trading around a ~
$100M market cap with only Phase 1 or very early clinical data and no major pharma partnerships:
• OKYO Pharma ~
$115M market cap, early clinical programs without organ-level proof
• IO Biotech ~
$140M market cap, early immune-oncology data
• Spero Therapeutics ~
$120M market cap, early-stage rare disease focus
• Vaxart ~
$100M or below market cap, early vaccine platform
• Prelude Therapeutics ~ around
$100M market cap, early oncology programs
• Organovo historically traded around this range with very early development
Most of these companies are valued on hope, PK/PD signals, or basic biomarker trends, not on proof that the drug works in the target organ.
Now compare that to Cardiol. ARCHER delivered MRI-based structural heart improvement, MAVERIC is already in Phase 3 territory for an orphan indication, Yet
$CRDL is still priced like a Phase 1 biotech.
That disconnect is the opportunity. DYOR.
